# Alzheimer's Disease Research Center

> **NIH NIH P30** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $423,750

## Abstract

SUMMARY
Recent research diagnostic criteria for Alzheimer’s Disease require biomarker evaluation (as with
neuroimaging and/or cerebrospinal fluid) of brain β Amyloid plaques, Tau tangles, and Neurodegeneration
(A/T/N), enabling detection of the presence (or absence) of AD neuropathology in living individuals, and
allowing AD to be diagnosed and staged while intervention maybe be feasible. The proposed supplement
seeks to acquire prospective PET and MRI data in accordance with the NIH-sponsored SCAN protocols to
classify individuals using the A/T/N framework, specifically for minority participants in the Mount Sinai ADRC
Clinical Cohort to enable examination of racial disparities in the prevalence of A/T/N biomarkers and their
association with cognition and other factors. Acquisition of A/T/N profiles in minority cohorts are of particular
significance because dementia of the Alzheimer’s type disproportionately impacts minority populations
(particularly African American and Hispanic populations in the United States). Despite higher prevalence rates
among minorities, they are less likely to receive a diagnosis of Alzheimer’s disease or are more likely to be
diagnosed later in the disease than their comparable non-minority counterparts. The proposed supplement
seeks to help fill this gap by providing data on a minority that can be widely distributed among the Alzheimer’s
disease research community. The cohort maintained by the Mount Sinai Alzheimer’s Disease Research Center
is well-suited to examine racial disparities in imaging biomarkers given that over 40% of the cohort is
comprised of minority participants. The supplement aims will: 1) establish the SCAN acquisition and data
transfer protocols at our site and validate the on-site scanner, 2) acquire the SCAN protocol on a minority
cohort of 40 participants at Mount Sinai sufficient to characterize individuals using the A/T/N framework, and 3)
examine whether low prevalence of amyloidosis among memory-impaired minority participants can be
explained by higher prevalence of tauopathy, neurodegeneration, or vascular burden. These aims have both
practical and scientific significance and will result in data using the standardized SCAN protocol on an
underserved population that can be widely shared and distributed to further Alzheimer’s disease research.
Scientific significance will be achieved by comparing the data acquired through the supplement with non-
minority participants characterized on SCAN-compatible protocols acquired with other resources to examine
racial disparities in biomarker profiles.

## Key facts

- **NIH application ID:** 10173338
- **Project number:** 3P30AG066514-01S1
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Mary Sano
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $423,750
- **Award type:** 3
- **Project period:** 2020-05-01 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10173338

## Citation

> US National Institutes of Health, RePORTER application 10173338, Alzheimer's Disease Research Center (3P30AG066514-01S1). Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/grant/nih/10173338. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*